维生素E及其在神经退行性疾病实验模型中的分子作用
Bianca Caroline da Cunha Germano1, Lara Cristina Carlos de Morais2,3, Francisca Idalina Neta3,4
1Postgraduate Program in Science Applied to Women's Health, Federal University of Rio Grande do Norte (UFRN), Natal 59072-970, Brazil.
International journal of molecular sciences
|July 14, 2023
概括
维生素E补充剂在保护大脑细胞免受氧化应激和改善认知功能方面表现有前途. 这篇评论强调了它在预防和减缓阿尔茨海默氏症等神经退行性疾病方面的潜力.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病的发病因子越来越多地通过体内研究和临床试验来理解.
- 氧化应激有助于神经退行性疾病中神经元损伤.
- 维生素E显示出对抗氧化应激的神经保护性.
研究的目的:
- 审查关于维生素E补充对神经保护的影响的科学证据.
- 在实验模型中评估维生素E对神经退行症标记物的影响.
主要方法:
- 在PubMed,Web of Science,BVS和Embase数据库中进行系统的文献搜索.
- 包括在2000年至2023年间发表的研究,研究实验性神经退行模型中的维生素E.
- 严格的排除标准被应用,导致19个出版物用于审查.
主要成果:
- 补充维生素E可以改善记忆,认知,学习和运动功能.
- 它减少了阿尔茨海默病模型中的β-粉样蛋白 (Aβ) 沉积和毒性.
- 维生素E降低了陶蛋白的高酸化,并增加了超氧化解突酶和BDNF水平.
结论:
- 维生素E补充剂在实验模型中表现出显著的神经保护作用.
- 它有可能预防和延迟中枢神经系统退行性病变的进展.
- 进一步研究维生素E在神经退行性疾病中的治疗作用是有必要的.
相关概念视频
Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


